Allogeneic stem cell transplantation for multiple myeloma

Reviews in Clinical and Experimental Hematology

Volumn 6, Issue 3, 2002, Pages 205-224

  Bellucci, Roberto ^a   Ritz, Jerome ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; MELPHALAN; PREDNISONE; T LYMPHOCYTE RECEPTOR; TACROLIMUS;

ALLOGENIC BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS MYELOMA EFFECT; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; REVIEW; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE TRANSFUSION; METHODOLOGY;

GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; MULTIPLE MYELOMA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036760085     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2002.00075.x     Document Type: Review

References (90)

1. Cigudosa JC, Rao PH, Calasanz MJ, et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood, 91: 3007-3010, 1998.
2. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood. 91: 3-21, 1998.
3. Sawyer JR, Lukacs JL, Munshi N, et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood. 92: 4269-4278, 1998.
4. Seidel C, Sundan A, Hjorth M, et al. Serum syndecan-1: A new independent prognostic marker in multiple myeloma. Blood, 95: 388-392, 2000.
5. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med, 336: 1657-1664, 1997.
6. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med, 330: 484-489, 1994.
7. Barlogie B, Alexanian R, Jagannath S. Plasma cell dyscrasias. JAMA, 268: 2946-2951, 1992.
8. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95: 4008-4010, 2000.
9. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood, 95: 7-11, 2000.
10. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93: 55-65, 1999.
11. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. Blood, 88: 2787-2793, 1996.
12. Cavo M, Bandini G, Benni M, et al. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant, 22: 27-32, 1998.
13. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol, 13: 1312-1322, 1995.
14. Rondelli D, Bandini G, Cavo M, et al. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: A case report. Bone Marrow Transplant, 24: 685-687, 1999.
15. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: Proof of principle. Blood, 87: 1196-1198, 1996.
16. Verdonck LF, Lokhorst HM, Dekker AW, et al. Graft-versus-myeloma effect in two cases. Lancet, 347: 800-801, 1996.
17. Alyea E, Weller E, Schlossman R, et al. Outcome After Autologous and Allogeneic Stem Cell Transplantation for Patients with Multiple Myeloma: Impact of Graft Versus Myeloma Effect. Submitted, 2002.
18. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol, 18: 2273-2281, 2000.
19. Reece DE, Shepherd JD, Klingemann HG, et al. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant, 15: 117-123, 1995.
20. Le Blanc R, Montminy-Metivier S, Belanger R, et al. Allogeneic transplantation for multiple myeloma: Further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant, 28: 841-848, 2001.
21. Reynolds C, Ratanatharathorn V, Adams P, et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant, 27: 801-807, 2001.
22. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med, 325: 1267-1273, 1991.
23. Alyea E, Weller E, Schlossman R, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect. Blood, 98: 934-939, 2001.
24. Cavo M, Terragna C, Martinelli G, et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood, 96: 355-357, 2000.
25. Alexanian R, Dimopoulos MA, Hester J, et al. Early myeloablative therapy for multiple myeloma. Blood, 84: 4278-4282, 1994.
26. Anderson KC. Who benefits from high-dose therapy for multiple myeloma? J Clin Oncol, 13: 1291-1296, 1995.
27. Russell NH, Miflin G, Stainer C, et al. Allogeneic bone marrow transplant for multiple myeloma. Blood, 89: 2610-2611, 1997.
28. Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood, 88: 4711-4718, 1996.
29. Bensinger WI, Demirer T, Buckner CD, et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant, 18: 527-531, 1996.
30. Osserman EF, DiRe LB, DiRe J, et al. Identical twin marrow transplantation in multiple myeloma. Acta Haematol, 68: 215-223, 1982.
31. Wolff SN, McCurley TL, Giannone L. High-dose chemoradiotherapy with syngeneic bone marrow transplantation for multiple myeloma: A case report and literature review. Am J Hematol, 26: 191-198, 1987.
32. Gahrton G, Svensson H, Bjorkstrand B, et al. Syngeneic transplantation in multiple myeloma - A case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant, 24: 741-745, 1999.
33. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome. J Clin Oncol, 18: 3031-3037, 2000.
34. Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant, 26: 1179-1184, 2000.
35. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4 (+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood, 91: 3671-3680, 1998.
36. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood, 90: 4206-4211, 1997.
37. Porter DL, Roth MS, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med, 330: 100-106, 1994.
38. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol, 15: 433-444, 1997.
39. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood, 86: 2041-2050, 1995.
40. Porter DL, Collins RH Jr, Shpilberg O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant, 5: 253-261, 1999.
41. Bertz H, Burger JA, Kunzmann R, et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect. Leukemia, 11: 281-283, 1997.
42. Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant, 22: 835-843, 1998.
43. Orsini E, Alyea EP, Schlossman R, et al. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant, 25: 623-632, 2000.
44. Orsini E, Alyea EP, Chillemi A, et al. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant, 6: 375-386, 2000.
45. Mackall CL, Granger L, Sheard MA, et al. T-cell regeneration after bone marrow transplantation: Differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood, 82: 2585-2594, 1993.
46. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med, 332: 143-149, 1995.
47. Mackall CL, Hakim FT, Gress RE. T-cell regeneration: All repertoires are not created equal. Immunol Today, 18: 245-251, 1997.
48. Rocha B, Dautigny N, Pereira P. Peripheral T lymphocytes: Expansion potential and homeostatic regulation of pool sizes and CD4/CD8 ratios in vivo. Eur J Immunol, 19: 905-911, 1989.
49. Hochberg EP, Chillemi AC, Wu CJ, et al. Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood, 98: 1116-1121, 2001.
50. Dumont-Girard F, Roux E, van Lier RA, et al. Reconstitution of the T-cell compartment after bone marrow transplantation: Restoration of the repertoire by thymic emigrants. Blood, 92: 4464-4471, 1998.
51. Roux E, Helg C, Chapuis B, et al. T-cell repertoire complexity after allogeneic bone marrow transplantation. Hum Immunol, 48: 135-138, 1996.
52. Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood, 96: 2299-2303, 2000.
53. Claret EJ, Alyea EP, Orsini E, et al. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest, 100: 855-866, 1997.
54. Wu CJ, Chillemi A, Alyea EP, et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood, 95: 352-359, 2000.
55. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature, 396: 690-695, 1998.
56. Douek DC, Vescio RA, Betts MR, et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet, 355: 1875-1881, 2000.
57. Storek J, Joseph A, Espino G, et al. Immunity of patients surviving 20-30 years after allogeneic or syngeneic bone marrow transplantation. Blood, 98: 3505-3512, 2001.
58. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood, 97: 1458-1466, 2001.
59. Bellucci R, Alyea E, Weller E, et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood, 99: 4610-4617, 2002.
60. Soiffer RJ, Freedman AS, Neuberg D, et al. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant, 21: 1177-1181, 1998.
61. Soiffer RJ, Bosserman L, Murray C, et al. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood, 75: 2076-2084, 1990.
62. Osterborg A, Yi Q, Henriksson L, et al. Idio-type immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood, 91: 2459-2466, 1998.
63. Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy. Blood, 94: 673-683, 1999.
64. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study. Blood, 93: 2411-2419, 1999.
65. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet, 345: 1016-1020, 1995.
66. Barratt-Boyes SM. Making the most of mucin: A novel target for tumor immunotherapy. Cancer Immunol Immunother, 43: 142-151, 1996.
67. Noto H, Takahashi T, Makiguchi Y, et al. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol, 9: 791-798, 1997.
68. Takahashi T, Makiguchi Y, Hinoda Y, et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol, 153: 2102-2109, 1994.
69. Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol, 166: 6555-6563, 2001.
70. Tanaka Y, Koido S, Chen D, et al. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol, 101: 192-200, 2001.
71. Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood, 93: 4309-4317, 1999.
72. van Baren N, Brasseur F, Godelaine D, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood, 94: 1156-1164, 1999.
73. Dhodapkar KM, Krasovsky J, Williamson B, et al. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med, 195: 125-133, 2002.
74. Nishikawa H, Tanida K, Ikeda H, et al. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci USA, 98: 14571-14576, 2001.
75. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA, 92: 11810-11813, 1995.
76. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med, 187: 1163-1167, 1998.
77. Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 106: 705-714, 2000.
78. Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol, 9: 709-716, 1997.
79. Jager E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptidevaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA, 97: 12198-12203, 2000.
80. Bellucci R, Wu C, Munshi N, et al. Identification of target antigens associated with graft-vs-myeloma response after allogeneic bone marrow transplantation and donor lymphocyte infusion. In: ASH. Blood (ed). American Society of Hematology, Orlando, p 405a, 2001.
81. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood, 94: 3234-3241, 1999.
82. Craddock C. Nonmyeloablative stem cell transplants. Curr Opin Hematol, 6: 383-387, 1999.
83. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood, 89: 4531-4536, 1997.
84. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol, 16: 2817-2824, 1998.
85. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91: 756-763, 1998.
86. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 97: 2574-2579, 2001.
87. Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol, 20: 1295-1303, 2002.
88. Ornstein DL, Ririe DW, Shaughnessy PJ, et al. Nonmyeloablative allogeneic peripheral blood stem cell transplantation for multifocal extramedullary plasmacytomas progressing after autologous transplantation. Bone Marrow Transplant, 29: 71-74, 2002.
89. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation, 68: 480-484, 1999.
90. Yang XF, Wu CJ, McLaughlin S, et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci USA, 98: 7492-7497, 2001.